KRAS and non-small cell lung carcinoma: This randomized, open-label trial compared adagrasib to docetaxel in patients with locally advanced or metastatic KRAS G12C-mutated NSCLC who had received prior platinum-based chemotherapy and anti-PD-(L)1 therapy, either sequentially or concomitantly.